ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… ProQR Announces Upcoming Investor Conferences in November and … & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived …
… ProQR Announces Results for the Third Quarter of 2017 Key … Scott Armstrong and Thaddeus (Ted) Dryja appointed to ProQR’s Scientific Advisory Board (SAB). In vivo proof of … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
… ProQR Announces Third Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We will enter 2021 with the Illuminate trial of …
… ProQR Announces Second Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We have continued to enroll patients in trials for …